Ono chases Takeda in polycythemia
Ono's antisense therapy is to begin its first pivotal trial.
Like Sanofi, German Merck keeps the CEACAM5 faith
Precemtabart tocentecan could soon become the industry's most advanced anti-CEACAM5 ADC.
Revolution’s big reveal approaches
The group’s first pivotal readout, in second-line pancreatic cancer, is coming.
Merck also goes for all-comers in adjuvant lung
The Kandlelit-013 trial of calderasib plus Keytruda in adjuvant NSCLC will start in April.
Takeda aims at Bristol and Merck
The Japanese group will soon start a trial of its Reblozyl rival in first-line MDS.
CytomX emerges from masked obscurity
But now it must show that varseta-M can move into a registrational trial.
Spurned by Sanofi, Orano turns to Roche
The first fruit of a long-standing deal with Roche enters phase 1 in March.
BioNTech's patritumab me-too advances
The company's partner MediLink will start a pivotal trial of beruzatatug pelitecan in lung cancer.
Genmab taps ProfoundBio again
After several discontinuations, a new ADC enters the clinic.
The non-covalent BTK space expands
Hutchmed goes pivotal with HMPL-760 in B-cell lymphoma.
